C028P: Camrelizumab Biosimilar, PD-1 Monoclonal Antibody
Recombinant Humanized IgG4-k Monoclonal Antibody.
Specificity/Sensitivity: The in vivo grade camrelizumab biosimilar specifically binds to the programmed cell death protein 1 (PD1), antagonizing its interaction with its known ligands PD-L1 and PD-L2.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by camrelizumab.